PEPTIDES FOR TREATMENT OF SEPSIS AND CANCER
The present invention provides oligopeptidic compounds comprising a first oligopeptidic component derived from SLAMF1 and a second oligopeptidic component which is a cell-penetrating peptide. The oligopeptidic compounds provided have been found unexpectedly to block signalling from TLR4, TLR7, TLR8...
Saved in:
Main Authors | , , |
---|---|
Format | Patent |
Language | English French German |
Published |
19.04.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention provides oligopeptidic compounds comprising a first oligopeptidic component derived from SLAMF1 and a second oligopeptidic component which is a cell-penetrating peptide. The oligopeptidic compounds provided have been found unexpectedly to block signalling from TLR4, TLR7, TLR8 and TLR9 in response to stimulus by their ligands, and also to display an anti-proliferative effect on cancer cells. The oligopeptidic compounds provided may be used in therapy for conditions associated with overactive immune responses, such as sepsis, and for treatment of cancer. |
---|---|
Bibliography: | Application Number: EP20210733102 |